Health Dictionary Find a Doctor

Guillain-Barré syndrome

For patient information click, here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Synonyms and keywords: Acute inflammatory demyelinating polyradiculoneuropathy

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Guillain-Barré syndrome (GBS) is an acute, autoimmune, polyradiculoneuropathy affecting the peripheral nervous system, usually triggered by an acute infectious process. It is included in the wider group of peripheral neuropathies.

Historical Perspective

The disease was first described by the French physician Jean Landry in 1859. In 1916, Georges Guillain, Jean Alexandre Barré and Andre Strohl diagnosed two soldiers with motor weakness, areflexia and a the key diagnostic abnormality of increased spinal fluid protein production, but normal cell count. Later, it was called Guillain-Barré syndrome after them. GBS is also known as acute inflammatory demyelinating polyneuropathy, acute idiopathic polyradiculoneuritis, acute idiopathic polyneuritis, French Polio and Landry’s ascending paralysis.

Classification

Guillain Barre syndrome may be classified according to the underlying pathophysiology into four groups: Acute motor axonal neuropathy (AMAN), acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy and Miller Fisher syndrome.

Pathophysiology

The exact pathogenesis of Guillain Barre syndrome is not completely understood but in 2/3 of cases there is a history of an infectious disease in the past month.The most common pathogens responsible for these antecedent infections are: Campylobacter jejuni, cytomegalo virus and Hemophilus influenzae. It is believed that the main underlying etiology of GBS is an autoimmune reaction due to molecular mimicry. On microscopic histopathological analysis: Lymphocyte and macrophage infiltration, demyelination in AIDP, Macrophage infiltration and axolemma disruption in motor fibers in AMAN, disruption of both motor and sensory fibers. Little lymphocyte infiltration in AMSAN and Oculomotor nerve demyelination in Miller Fisher type.

Causes

Guillain Barre syndrome may be caused by Campylobacter jejuni, Cytomegalovirus, haemophilus influenza, epstein-Barr virus, Varicella zoster virus and HIV-1.

Differentiating Guillain-Barré syndrome from other diseases

Guillain Barre syndrome must be differentiated from: Acute Flaccid Myelitis, adult botulism, infant botulism, Eaton-Lambert syndrome, myasthenia gravis, electrolyte disturbance, organophosphate toxicity, tick paralysis, tetrodotoxin poisoning, stroke, poliomyelitis, transverse myelitis, neurosyphilis, muscular dystrophy, multiple sclerosis exacerbation, amyotrophic lateral sclerosis and inflammatory myopathy.

Epidemiology and Demographics

Incidence vary from 0.4 to 4.0 cases per population of 100 000. In previous studies, Guillain-Barre syndrome mortality rate was 2.58%. It can happen in any age group but it’s more common in late adolescence. The reason behind this is that immune suppressor mechanisms will decrease with age. It was demonstrated in one study that the incidence rate for whites were 0.44 and for blacks were 0.28 per 100,000, but it seems that despite all of these, the incidence is similar across different races. It is more common among males compared to females. Male to female ratio 1.5:1.

Risk Factors

Risk factors in the development of Guillain Barre syndrome include: Rabies vaccine and swine-flu influenza vaccine.

Screening

There is insufficient evidence to recommend routine screening for Guillain Barre syndrome.

Natural History, Complications and Prognosis

The symptoms of Guillain Barre syndrome typically develop 1 to 3 weeks after the Antecedent Infection. If left untreated, 65% of patients with Guillain Barre syndrome will recover with no permanent disability. 35% of them will not fully recover. 8% of these 35% will die from complication and others will have permanent disabilities.

Common complications of GBS include: respiratory failure, autonomic failure, bulbar pulsy, Deep vein thrombosis, Cardiac arrhythmia, Pain, Urinary retention, Ileus and persistent fatigue

Diagnosis

Diagnostic Study of Choice

There is no single diagnostic study of choice for Guillain Barre syndrome, though GBS may be diagnosed based on NINDS criteria established by National Institute of Neurological Disorders and Stroke: Progressive ascending weakness or paralysis usually starting from legs, involving are 4 limbs, the trunk, bulbar and facial muscles, and external ocular muscles and Areflexia or decreased reflexes in affected limbs.

History and Symptoms

Patients with Guillain Barre syndrome may have a positive history of: Prior infection with Campylobacter jejuni, Cytomegalovirus, Haemophilus influenzae, Epstein-Barr virus, Varicella zoster virus and HIV-1, recent vaccination with influenzae or rabies vaccine, limb tingling and paresthesia, lower extremity weakness and muscle pain.

Common symptoms of Guillain Barre syndrome include: Symmetrical ascending weakness and paralysis, tingling and paresthesia and pain.

Physical Examination

Physical examination of patients with Guillain Barre syndrome is usually remarkable for abnormal gait, heart rate and blood pressure disturbance, ophthalmoplegia, papilledema, facial myokymia, vocal cord paralysis, urinary retention, hyperreflexia or areflexia, bilateral distal and proximal muscle weakness and unilateral or bilateral sensory abnormality.

Laboratory Findings

Laboratory findings consistent with the diagnosis of Guillain Barre syndrome include: Elevated CSF protein level, normal CSF WBC count, normal CSF cell count (in some cases there is mildly elevated cell count) and serum IgG antibody to GQ1b in Miller Fisher syndrome.

Electrocardiogram

The dysautonomia seen in Guillian Barre syndrome may lead to some conduction and rhythm disturbances. Findings on an ECG suggestive of Guillain Barre syndrome include: ST segment depresion, T wave inversion, QT prolongation and Ttachycardia.

X-Ray

There are no characteristic x-Ray findings associated with Guillain Barre disease.

Echocardiography/Ultrasound

There are no characteristic echocardiography/ultrasound findings associated with Guillain Barre syndrome.

CT Scan

There are no characteristic CT scan findings associated with Guillain Barre syndrome but we can perform CT scan to exclude other etiologies.

MRI

Findings on MRI suggestive of Guillain Barre syndrome include: Anterior and posterior nerve root and cauda equina enhancement.

Other Imaging Findings

There are no other imaging findings associated with Guillain Barre sydnrome.

Other Diagnostic Studies

Nerve conduction studies and needle electromyography may be helpful in the diagnosis of Guillain Barre syndrome and differentiating various sub types. Findings diagnostic of demyelinating forms of Guillain Barre syndrome include: Reduced conduction velocity of motor nerves, increased distal motor latency, increased latency of F wave, conduction block and Temporal scattering. Findings diagnostic of axonal forms of Guillain Barre syndrome include: Reduced amplitude of distal motor and/or sensory nerve impulses and conduction block of motor nerves.

Treatment

Medical Therapy

Supportive therapy for Guillain Barre syndrome include: Respiratory assistance, Heart rate and blood pressure monitoring, prevention of thromboembolic complications by heparin, minimal sedation in intensive care units, pain control and early passive movements. Immunomodulating therapy for Guillain Barre syndrome include: Plasma exchange, High dose immunoglobulin and Corticosteroids.

Surgery

Surgical intervention is not recommended for the management of Guillain Barre syndrome.

Primary Prevention

There are no established measures for the primary prevention of Guillain Barre syndrome.

Secondary Prevention

References

Template:WH Template:WS

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Priyamvada Singh, MBBS [2]

Overview

The disease was first described by the French physician Jean Landry in 1859. In 1916, Georges Guillain, Jean Alexandre Barré and Andre Strohl diagnosed two soldiers with motor weakness, areflexia and a the key diagnostic abnormality of increased spinal fluid protein production, but normal cell count. Later, it was called Guillain-Barré syndrome after them. GBS is also known as acute inflammatory demyelinating polyneuropathy, acute idiopathic polyradiculoneuritis, acute idiopathic polyneuritis, French Polio and Landry’s ascending paralysis.

Historical Perspective

Discovery

Famous Cases

File:Griffith, Andy (Whitehouse).jpg
American actor Andy Griffith developed Guillain-Barré syndrome in 1983. Griffith is seen here receiving an award at the White House in 2005
  • Markus Babbel, former international footballer.[2]
  • Tony Benn, British politician.[3]
  • Rachel Chagall, actress.[4]
  • Samuel Goldstein, American athlete and Paralympian.[5]
  • Andy Griffith, American actor.[6]
  • Joseph Heller, author.[7]
  • Luci Baines Johnson, daughter of President Lyndon Johnson and Lady Bird Johnson.[8]
  • Hugh McElhenny, American football player.[9]
  • Lucky Oceans, Grammy Award-winning musician.[10]
  • Len Pasquarelli, sports writer and analyst for ESPN and resident of the Pro Football Writers of America.[11]
  • Serge Payer, Canadian-born professional hockey player.[12]
  • William “The Refrigerator” Perry, former professional American football player.[13]
  • Franklin D. Roosevelt, U.S. president.[14]
  • Norton Simon, American industrialist and philanthropist.[15]
  • Hans Vonk, Dutch conductor.[16]
  • Danny Wuerffel, 1996 Heisman Trophy winner.[17]

References

  1. Template:WhoNamedIt2 and Template:WhoNamedIt
  2. Wallace, Sam (2002-08-10). “Grateful Babbel a tower of strength again”. London: Telegraph. Retrieved 2009-11-23.
  3. Lea, Robert (2002-10-17). “Relative Values: Tony and Josh Benn”. London: The Times. Retrieved 2009-01-15.
  4. “Gaby, A True Story (1987)”. Films involving Disabilities.
  5. The case of Sam Goldstein and the swine flu vaccine, jta.org, May 5, 2009
  6. “Andy in Guideposts Magazine”.
  7. Vogel, Speed; Heller, Joseph (2004). No Laughing Matter. New York: Simon & Schuster. ISBN 0-7432-4717-5.
  8. “Luci Baines Johnson hospitalized with nervous system disorder”.
  9. Raley, Dan (2004-09-02). “The untold story of Hugh McElhenny, the King of Montlake”. Seattle PI. Retrieved 2010-01-07.
  10. “Lucky Oceans in hospital”. The Australian. 2008-10-13. Retrieved 2008-10-28.
  11. “Chris Mortensen on Len Pasquarelli’s comeback”. ESPN.com. 2009-01-26. Retrieved 2009-01-26.
  12. Serge Payer Foundation, Serge Payer Foundation Mission.
  13. . YumaSun.com. 2008-09-08 http://www.yumasun.com/sports/tatum_44249___article.html/perry_night.html. Retrieved 2008-10-28. Missing or empty |title= (help)
  14. Goldman AS, Schmalstieg EJ, Freeman DH, Goldman DA, Schmalstieg FC (2003). “What was the cause of Franklin Delano Roosevelt’s paralytic illness?” (PDF). J Med Biogr. 11 (4): 232–40. PMID 14562158. Retrieved 2010-08-07.
  15. “Norton Simon Biography”. Retrieved 13 October 2009.
  16. Kozinn, Allan (2004-08-31). “Hans Vonk, 63, Conductor Of the St. Louis Symphony”. The New York Times. Retrieved 2009-08-26.
  17. Dooley, Pat. “Wuerffel hospitalized to treat nervous system disorder”. Gatorsports.com. Retrieved 16 June 2011.

Template:WH Template:WS

Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Guillain Barre syndrome may be classified according to the underlying pathophysiology into four groups: Acute motor axonal neuropathy (AMAN), acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy and Miller Fisher syndrome.

Classification

Guillain Barre syndrome may be classified according to the underlying pathophysiology into four groups:[1][2][3][4][5][6][7][8][9]

Subtypes Explanation
Acute Motor Axonal Neuropathy (AMAN)
Acute Motor Axonal Neuropathy (AMAN)
Acute motor and sensory axonal neuropathy
Miller Fisher syndrome

References

  1. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV (November 1998). “Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group”. Ann. Neurol. 44 (5): 780–8. doi:10.1002/ana.410440512. PMID 9818934.
  2. Prineas JW (February 1972). “Acute idiopathic polyneuritis. An electron microscope study”. Lab. Invest. 26 (2): 133–47. PMID 5059983.
  3. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM (June 1995). “Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies”. Brain. 118 ( Pt 3): 597–605. PMID 7600081.
  4. Prineas JW (1981). “Pathology of the Guillain-Barré syndrome”. Ann. Neurol. 9 Suppl: 6–19. PMID 7224616.
  5. Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, Noda M (August 1998). “IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome”. Ann. Neurol. 44 (2): 202–8. doi:10.1002/ana.410440210. PMID 9708542.
  6. Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N (October 2000). “Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan”. Ann. Neurol. 48 (4): 624–31. PMID 11026446.
  7. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, Mishu B, Cornblath DR, Macko C, McKhann GM, Asbury AK (January 1996). “Pathology of the motor-sensory axonal Guillain-Barré syndrome”. Ann. Neurol. 39 (1): 17–28. doi:10.1002/ana.410390105. PMID 8572662.
  8. FISHER M (July 1956). “An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia)”. N. Engl. J. Med. 255 (2): 57–65. doi:10.1056/NEJM195607122550201. PMID 13334797.
  9. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T (November 1993). “A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure”. J. Exp. Med. 178 (5): 1771–5. PMC 2191246. PMID 8228822.

Template:WH Template:WS

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

The exact pathogenesis of Guillain Barre syndrome is not completely understood but in 2/3 of cases there is a history of an infectious disease in the past month.The most common pathogens responsible for these antecedent infections are: Campylobacter jejuni, cytomegalo virus and Hemophilus influenzae. It is believed that the main underlying etiology of GBS is an autoimmune reaction due to molecular mimicry. On microscopic histopathological analysis: Lymphocyte and macrophage infiltration, demyelination in AIDP, Macrophage infiltration and axolemma disruption in motor fibers in AMAN, disruption of both motor and sensory fibers. Little lymphocyte infiltration in AMSAN and Oculomotor nerve demyelination in Miller Fisher type.

Pathophysiology

Physiology

  • Dendrites are branched processes which lead the impulse into the neuronal cell body.
  • Axons in a single process which lead the impulse away from the neuronal cell body.
  • This structure leads to fast traveling of electrical impulses.[1]

Pathogenesis

Genetics

  • There is no characteristic genetic association with GBS.

Microscopic Pathology

References

  1. Mattle, Heinrich (2017). Fundamentals of neurology : an illustrated guide. Stuttgart New York: Thieme. ISBN 9783131364524.
  2. Winer JB, Hughes RA, Anderson MJ, Jones DM, Kangro H, Watkins RP (May 1988). “A prospective study of acute idiopathic neuropathy. II. Antecedent events”. J. Neurol. Neurosurg. Psychiatry. 51 (5): 613–8. PMC 1033063. PMID 3404161.
  3. Jacobs BC, Rothbarth PH, van der Meché FG, Herbrink P, Schmitz PI, de Klerk MA, van Doorn PA (October 1998). “The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study”. Neurology. 51 (4): 1110–5. PMID 9781538.
  4. Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N (October 2000). “Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan”. Ann. Neurol. 48 (4): 624–31. PMID 11026446.
  5. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T (November 1993). “A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure”. J. Exp. Med. 178 (5): 1771–5. PMC 2191246. PMID 8228822.
  6. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I (October 1993). “Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies”. Neurology. 43 (10): 1911–7. PMID 8413947.
  7. Irie S, Saito T, Nakamura K, Kanazawa N, Ogino M, Nukazawa T, Ito H, Tamai Y, Kowa H (August 1996). “Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection”. J. Neuroimmunol. 68 (1–2): 19–26. PMID 8784256.
  8. Mori M, Kuwabara S, Miyake M, Dezawa M, Adachi-Usami E, Kuroki H, Noda M, Hattori T (April 1999). “Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain-Barré syndrome”. Neurology. 52 (6): 1282–4. PMID 10214761.
  9. 9.0 9.1 Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, Asbury AK, Griffin JW (May 1996). “Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy”. Ann. Neurol. 39 (5): 625–35. doi:10.1002/ana.410390512. PMID 8619548.
  10. 10.0 10.1 Hafer-Macko C, Hsieh ST, Li CY, Ho TW, Sheikh K, Cornblath DR, McKhann GM, Asbury AK, Griffin JW (October 1996). “Acute motor axonal neuropathy: an antibody-mediated attack on axolemma”. Ann. Neurol. 40 (4): 635–44. doi:10.1002/ana.410400414. PMID 8871584.
  11. 11.0 11.1 Ganser AL, Kirschner DA (1984). “Differential expression of gangliosides on the surfaces of myelinated nerve fibers”. J. Neurosci. Res. 12 (2–3): 245–55. doi:10.1002/jnr.490120212. PMID 6502752.
  12. 12.0 12.1 Feasby TE, Hahn AF, Brown WF, Bolton CF, Gilbert JJ, Koopman WJ (June 1993). “Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms?”. J. Neurol. Sci. 116 (2): 185–92. PMID 8336165.
  13. 13.0 13.1 Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, Zochodne DW (December 1986). “An acute axonal form of Guillain-Barré polyneuropathy”. Brain. 109 ( Pt 6): 1115–26. PMID 3790970.
  14. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I (October 1993). “Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies”. Neurology. 43 (10): 1911–7. PMID 8413947.
  15. Phillips MS, Stewart S, Anderson JR (May 1984). “Neuropathological findings in Miller Fisher syndrome”. J. Neurol. Neurosurg. Psychiatry. 47 (5): 492–5. PMC 1027825. PMID 6736980.

Template:WH Template:WS

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Guillain Barre syndrome may be caused by Campylobacter jejuni, Cytomegalovirus, haemophilus influenza, epstein-Barr virus, Varicella zoster virus and HIV-1.

Causes

Life-threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. GBS has a different natural history in every patient based on age and the speed of symptoms occurrence, so it can lead to death or patients may fully recover no matter what the etiology is.[1][2]

Common Causes

Less Common Causes

References

  1. Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV (November 1998). “Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group”. Ann. Neurol. 44 (5): 780–8. doi:10.1002/ana.410440512. PMID 9818934.
  2. Bradshaw DY, Jones HR (April 1992). “Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis”. Muscle Nerve. 15 (4): 500–6. doi:10.1002/mus.880150415. PMID 1565119.
  3. Hughes RA, Rees JH (December 1997). “Clinical and epidemiologic features of Guillain-Barré syndrome”. J. Infect. Dis. 176 Suppl 2: S92–8. PMID 9396689.
  4. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM (June 1995). “Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies”. Brain. 118 ( Pt 3): 597–605. PMID 7600081.
  5. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T (November 1993). “A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure”. J. Exp. Med. 178 (5): 1771–5. PMC 2191246. PMID 8228822.
  6. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I (October 1993). “Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies”. Neurology. 43 (10): 1911–7. PMID 8413947.
  7. Kuwabara S, Ogawara K, Koga M, Mori M, Hattori T, Yuki N (August 1999). “Hyperreflexia in Guillain-Barré syndrome: relation with acute motor axonal neuropathy and anti-GM1 antibody”. J. Neurol. Neurosurg. Psychiatry. 67 (2): 180–4. PMC 1736477. PMID 10406985.
  8. 8.0 8.1 Winer JB, Hughes RA, Anderson MJ, Jones DM, Kangro H, Watkins RP (May 1988). “A prospective study of acute idiopathic neuropathy. II. Antecedent events”. J. Neurol. Neurosurg. Psychiatry. 51 (5): 613–8. PMC 1033063. PMID 3404161.
  9. Irie S, Saito T, Nakamura K, Kanazawa N, Ogino M, Nukazawa T, Ito H, Tamai Y, Kowa H (August 1996). “Association of anti-GM2 antibodies in Guillain-Barré syndrome with acute cytomegalovirus infection”. J. Neuroimmunol. 68 (1–2): 19–26. PMID 8784256.
  10. Mori M, Kuwabara S, Miyake M, Dezawa M, Adachi-Usami E, Kuroki H, Noda M, Hattori T (April 1999). “Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain-Barré syndrome”. Neurology. 52 (6): 1282–4. PMID 10214761.
  11. Berger JR, Difini JA, Swerdloff MA, Ayyar DR (September 1987). “HIV seropositivity in Guillain-Barré syndrome”. Ann. Neurol. 22 (3): 393–4. doi:10.1002/ana.410220320. PMID 3674806.

Template:WH Template:WS

Differentiating Guillain-Barré Syndrome from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Priyamvada Singh, MBBS [2]

Overview

Guillain-Barré syndrome is an acute, autoimmune, polyradiculoneuropathy affecting the peripheral nervous system, usually triggered by an acute infectious process. It is included in the wider group of peripheral neuropathies.

References

Template:WH Template:WS

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Incidence vary from 0.4 to 4.0 cases per population of 100 000. In previous studies, Guillain-Barre syndrome mortality rate was 2.58%. It can happen in any age group but it’s more common in late adolescence. The reason behind this is that immune suppressor mechanisms will decrease with age. It was demonstrated in one study that the incidence rate for whites were 0.44 and for blacks were 0.28 per 100,000, but it seems that despite all of these, the incidence is similar across different races. It is more common among males compared to females. Male to female ratio 1.5:1.

Epidemiology and Demographics

Incidence

  • Incidence vary from 0.4 to 4.0 cases per population of 100 000.[1]

Case mortality rate

  • In previous studies, Guillain-Barre syndrome mortality rate was 2.58%.[2]

Age

  • It can happen in any age group but it’s more common in late adolescence.
  • The reason behind this is that immune suppressor mechanisms will decrease with age.[1]

Races

  • It was demonstrated in one study that the incidence rate for whites were 0.44 and for blacks were 0.28 per 100,000, but it seems that despite all of these, the incidence is similar across different races.[3]

Gender

  • It is more common among males compared to females. Male to female ratio 1.5:1.[1]

References

  1. 1.0 1.1 1.2 Hughes RA, Rees JH (December 1997). “Clinical and epidemiologic features of Guillain-Barré syndrome”. J. Infect. Dis. 176 Suppl 2: S92–8. PMID 9396689.
  2. Alshekhlee A, Hussain Z, Sultan B, Katirji B (April 2008). “Guillain-Barré syndrome: incidence and mortality rates in US hospitals”. Neurology. 70 (18): 1608–13. doi:10.1212/01.wnl.0000310983.38724.d4. PMID 18443311.
  3. Hurwitz ES, Holman RC, Nelson DB, Schonberger LB (February 1983). “National surveillance for Guillain-Barré syndrome: January 1978-March 1979”. Neurology. 33 (2): 150–7. PMID 6681655.

Template:WH Template:WS

Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Risk factors in the development of Guillain Barre syndrome include: Rabies vaccine and swine-flu influenza vaccine.

Risk Factors

  • Risk factors in the development of Guillain Barre syndrome include:
    • There are some evidence demonstrating that there might be a connection between vaccination and Guillain Barre syndrome.

References

  1. Hemachudha T, Griffin DE, Chen WW, Johnson RT (March 1988). “Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome”. Neurology. 38 (3): 375–8. PMID 2450302.
  2. Safranek TJ, Lawrence DN, Kurland LT, Culver DH, Wiederholt WC, Hayner NS, Osterholm MT, O’Brien P, Hughes JM (May 1991). “Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group”. Am. J. Epidemiol. 133 (9): 940–51. PMID 1851395.

Template:WH Template:WS

Natural history, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Fahimeh Shojaei, M.D.

Overview

The symptoms of Guillain Barre syndrome typically develop 1 to 3 weeks after the Antecedent Infection. If left untreated, 65% of patients with Guillain Barre syndrome will recover with no permanent disability. 35% of them will not fully recover. 8% of these 35% will die from complication and others will have permanent disabilities.

Common complications of GBS include: respiratory failure, autonomic failure, bulbar pulsy, Deep vein thrombosis, Cardiac arrhythmia, Pain, Urinary retention, Ileus and persistent fatigue

Natural History, Complications, and Prognosis

Natural history

  • The symptoms of Guillain Barre syndrome typically develop 1 to 3 weeks after the Antecedent Infection.
  • If left untreated, 65% of patients with Guillain Barre syndrome will recover with no permanent disability.
  • 35% of them will not fully recover. 8% of these 35% will die from complication and others will have permanent disabilities.
  • Treatment will just reduce the recovery period and has no effect on natural history of the disease.
  • The first symptoms are lower extremities weakness and paresthesia.[1][2][3]

Complications

Prognosis

  • About 65% of patients with GBS will fully recover with no permanent disability.
  • 35% of them do not fully recover. 8% of this group will die from GBS complication and others will have permanent disabilities.
  • Treatment of GBS just reduce the recovery time and doesn’t affect prognosis.[6]
  • Overally, older patients will have worst prognosis in comparison to children who discover very fast.[1][2]

References

  1. 1.0 1.1 Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV (November 1998). “Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group”. Ann. Neurol. 44 (5): 780–8. doi:10.1002/ana.410440512. PMID 9818934.
  2. 2.0 2.1 Bradshaw DY, Jones HR (April 1992). “Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis”. Muscle Nerve. 15 (4): 500–6. doi:10.1002/mus.880150415. PMID 1565119.
  3. Mattle, Heinrich (2017). Fundamentals of neurology : an illustrated guide. Stuttgart New York: Thieme. ISBN 9783131364524.
  4. Dornonville de la Cour C, Jakobsen J (January 2005). “Residual neuropathy in long-term population-based follow-up of Guillain-Barré syndrome”. Neurology. 64 (2): 246–53. doi:10.1212/01.WNL.0000149521.65474.83. PMID 15668421.
  5. Meythaler JM (August 1997). “Rehabilitation of Guillain-Barré syndrome”. Arch Phys Med Rehabil. 78 (8): 872–9. PMID 9344309.
  6. Rees JH, Thompson RD, Smeeton NC, Hughes RA (January 1998). “Epidemiological study of Guillain-Barré syndrome in south east England”. J. Neurol. Neurosurg. Psychiatry. 64 (1): 74–7. PMC 2169900. PMID 9436731.

Template:WH Template:WS

Diagnosis

Diagnosis

Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | MRI | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Physical Therapy | Secondary Prevention

Case Study

Case Study

Case #1

Related Chapters

Template:WH

Template:WS

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH